Short answer
Boston Scientific (BSX) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Board expanded from 10 to 12 directors; Catherine R. Smith and Christophe P. Weber appointed effective Feb 18, 2026.
Boston Scientific 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 10 to 12 directors; Catherine R. Smith and Christophe P. Weber appointed effective Feb 18, 2026
- Each new director receives prorated cash retainer ~$24,663 (vs. $125,000 annual) and equity award ~$42,420 (vs. $215,000 annual)
- Equity grants priced March 2, 2026; vest at end of director term at 2026 Annual Meeting
- Smith joins Audit and Nominating/Governance Committees; Weber joins Executive Compensation and Risk, Science & Technology Committees
- Standard indemnification agreements to be executed; no related-party conflicts disclosed for either appointee
Item 7.01 · Regulation FD Disclosure
- Reg FD filing contains only standard non-incorporation disclaimer: no material business update, guidance, or data disclosed in this excerpt
Item 8.01 · Other Events
- Board approved $4.0B increase to share repurchase authorization on Feb 18, 2026, bringing total program to $5.0B
- Full $5.0B remains available: no buybacks executed against new authorization yet
- Large buyback signal: $5.0B represents significant capital return commitment, bullish on BSX valuation at current levels
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Boston Scientific 8-K filings
Get the next BSX 8-K as it lands
Follow BSX for push alerts, or ask the research agent what this filing means.